Bruker Debt to Equity Ratio 2012-2026 | BRKR
Current and historical debt to equity ratio values for Bruker (BRKR) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Bruker debt/equity for the three months ending March 31, 2026 was 0.75.
| Bruker Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2026-03-31 | $3.66B | $2.47B | 1.49 |
| 2025-12-31 | $3.77B | $2.47B | 1.52 |
| 2025-09-30 | $3.99B | $2.45B | 1.63 |
| 2025-06-30 | $4.52B | $1.82B | 2.49 |
| 2025-03-31 | $4.10B | $1.83B | 2.24 |
| 2024-12-31 | $4.01B | $1.80B | 2.23 |
| 2024-09-30 | $4.29B | $1.83B | 2.35 |
| 2024-06-30 | $4.10B | $1.81B | 2.27 |
| 2024-03-31 | $3.07B | $1.43B | 2.15 |
| 2023-12-31 | $2.86B | $1.40B | 2.05 |
| 2023-09-30 | $2.59B | $1.23B | 2.11 |
| 2023-06-30 | $2.61B | $1.25B | 2.08 |
| 2023-03-31 | $2.57B | $1.20B | 2.14 |
| 2022-12-31 | $2.49B | $1.13B | 2.21 |
| 2022-09-30 | $2.39B | $0.95B | 2.52 |
| 2022-06-30 | $2.40B | $0.98B | 2.44 |
| 2022-03-31 | $2.52B | $1.03B | 2.44 |
| 2021-12-31 | $2.57B | $1.09B | 2.37 |
| 2021-09-30 | $2.04B | $1.09B | 1.87 |
| 2021-06-30 | $2.07B | $1.02B | 2.04 |
| 2021-03-31 | $2.05B | $0.98B | 2.09 |
| 2020-12-31 | $2.08B | $0.97B | 2.13 |
| 2020-09-30 | $1.92B | $0.96B | 1.99 |
| 2020-06-30 | $2.04B | $0.91B | 2.25 |
| 2020-03-31 | $2.04B | $0.93B | 2.20 |
| 2019-12-31 | $1.85B | $0.92B | 2.02 |
| 2019-09-30 | $1.50B | $0.86B | 1.75 |
| 2019-06-30 | $1.48B | $0.87B | 1.70 |
| 2019-03-31 | $1.32B | $0.92B | 1.43 |
| 2018-12-31 | $1.22B | $0.91B | 1.35 |
| 2018-09-30 | $1.06B | $0.83B | 1.29 |
| 2018-06-30 | $1.02B | $0.79B | 1.30 |
| 2018-03-31 | $1.04B | $0.79B | 1.32 |
| 2017-12-31 | $1.22B | $0.73B | 1.66 |
| 2017-09-30 | $1.22B | $0.74B | 1.65 |
| 2017-06-30 | $1.15B | $0.76B | 1.51 |
| 2017-03-31 | $1.11B | $0.73B | 1.52 |
| 2016-12-31 | $1.12B | $0.69B | 1.61 |
| 2016-09-30 | $1.10B | $0.70B | 1.57 |
| 2016-06-30 | $1.05B | $0.67B | 1.57 |
| 2016-03-31 | $1.03B | $0.71B | 1.45 |
| 2015-12-31 | $1.00B | $0.73B | 1.36 |
| 2015-09-30 | $1.08B | $0.77B | 1.40 |
| 2015-06-30 | $1.05B | $0.77B | 1.37 |
| 2015-03-31 | $1.05B | $0.72B | 1.46 |
| 2014-12-31 | $1.09B | $0.77B | 1.42 |
| 2014-09-30 | $1.10B | $0.81B | 1.35 |
| 2014-06-30 | $1.12B | $0.89B | 1.26 |
| 2014-03-31 | $1.16B | $0.87B | 1.34 |
| 2013-12-31 | $1.14B | $0.85B | 1.34 |
| 2013-09-30 | $1.16B | $0.78B | 1.48 |
| 2013-06-30 | $1.08B | $0.72B | 1.49 |
| 2013-03-31 | $1.12B | $0.69B | 1.62 |
| 2012-12-31 | $1.15B | $0.71B | 1.62 |
| 2012-09-30 | $1.10B | $0.70B | 1.59 |
| 2012-06-30 | $1.11B | $0.64B | 1.73 |
| 2012-03-31 | $1.14B | $0.66B | 1.72 |
| 2011-12-31 | $1.09B | $0.63B | 1.74 |
| 2011-09-30 | $1.07B | $0.60B | 1.77 |
| 2011-06-30 | $1.07B | $0.63B | 1.70 |
| 2011-03-31 | $1.05B | $0.57B | 1.84 |
| 2010-12-31 | $1.02B | $0.53B | 1.94 |
| 2010-09-30 | $0.78B | $0.49B | 1.59 |
| 2010-06-30 | $0.73B | $0.41B | 1.76 |
| 2010-03-31 | $0.74B | $0.42B | 1.78 |
| 2009-12-31 | $0.75B | $0.42B | 1.80 |
| 2009-09-30 | $0.75B | $0.37B | 2.01 |
| 2009-06-30 | $0.75B | $0.34B | 2.23 |
| 2009-03-31 | $0.76B | $0.30B | 2.56 |
| 2008-12-31 | $0.80B | $0.31B | 2.57 |
| 2008-09-30 | $0.78B | $0.29B | 2.66 |
| 2008-06-30 | $0.86B | $0.31B | 2.79 |
| 2008-03-31 | $1.11B | $0.29B | 3.82 |
| 2007-12-31 | $0.68B | $0.64B | 1.06 |
| 2007-09-30 | $0.26B | $0.24B | 1.09 |
| 2007-06-30 | $0.24B | $0.22B | 1.08 |
| 2007-03-31 | $0.25B | $0.22B | 1.16 |
| 2006-12-31 | $0.24B | $0.19B | 1.26 |
| 2006-09-30 | $0.23B | $0.18B | 1.32 |
| 2006-06-30 | $0.16B | $0.22B | 0.74 |
| 2006-03-31 | $0.16B | $0.21B | 0.74 |
| 2005-12-31 | $0.19B | $0.23B | 0.85 |
| 2005-09-30 | $0.14B | $0.21B | 0.70 |
| 2005-06-30 | $0.14B | $0.21B | 0.70 |
| 2005-03-31 | $0.16B | $0.21B | 0.73 |
| 2004-12-31 | $0.15B | $0.22B | 0.71 |
| 2004-09-30 | $0.15B | $0.21B | 0.70 |
| 2004-06-30 | $0.14B | $0.21B | 0.66 |
| 2004-03-31 | $0.14B | $0.20B | 0.72 |
| 2003-12-31 | $0.15B | $0.20B | 0.73 |
| 2003-09-30 | $0.14B | $0.20B | 0.74 |
| 2003-06-30 | $0.09B | $0.13B | 0.67 |
| 2003-03-31 | $0.09B | $0.13B | 0.67 |
| 2002-12-31 | $0.16B | $0.19B | 0.85 |
| 2002-09-30 | $0.07B | $0.13B | 0.53 |
| 2002-06-30 | $0.07B | $0.13B | 0.56 |
| 2002-03-31 | $0.07B | $0.13B | 0.52 |
| 2001-12-31 | $0.06B | $0.13B | 0.48 |
| 2001-09-30 | $0.06B | $0.13B | 0.48 |
| 2001-06-30 | $0.06B | $0.12B | 0.50 |
| 2001-03-31 | $0.06B | $0.12B | 0.51 |
| 2000-12-31 | $0.06B | $0.12B | 0.48 |
| 2000-09-30 | $0.05B | $0.12B | 0.45 |
| 2000-06-30 | $0.06B | $0.01B | 6.23 |
| 2000-03-31 | $0.06B | $0.01B | 6.31 |
| 1999-12-31 | $0.06B | $0.01B | 5.70 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Computer and Technology | Scientific Instruments Manufacturing | $5.722B | $3.437B |
| Bruker Corp designs & manufactures proprietary life science & materials research systems & associated products that serve multiple customers in life science research, pharmaceuticals, applied markets, nanotechnology, cell biology, clinical research, microbiology & in-vitro diagnostics. BSI Life Science reports under two groups: Bruker BioSpin Group & Bruker CALID Group. The Bruker BioSpin comprises the Bruker Magnetic Resonance & Preclinical Imaging divisions, which designs, manufactures & distributes enabling life science tools based on the magnetic resonance technology. The Bruker CALID comprises the Bruker Daltonics & primarily designs, manufactures & distributes life-science mass spectrometry instruments that can be integrated with other sample preparation or chromatography instruments. BSI Nano designs, manufactures & distributes advanced X-ray instruments to determine the characteristics of matter & the three-dimensional structure of molecules. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kewaunee Scientific (KEQU) | United States | $0.100B | 8.24 |
| Harvard Bioscience (HBIO) | United States | $0.019B | 0.00 |